Article
Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Sept 2020
Lu C, Terbuch A, Dolling D, Yu J, Wang H, Chen Y, Fountain J, Bertan C, Sharp A, Carreira S, Isaacs W B, Antonarakis E S, De Bono J S, Luo J
Abstract excerpt
BACKGROUND: In men with castration-sensitive prostate cancer (CSPC), the HSD3B1 c.1245A>C variant has been reported to be associated with shorter responses to first-line androgen-deprivation therapy (ADT). Here, we evaluated the association between the inherited HSD3B1 c.1245A>C variant and outcomes from metastatic castration-resistant prostate cancer (mCRPC) after first-line treatment with abiraterone (Abi) or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.